1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Dr. Buyon has received consulting fees and/or honoraria from Amgen, Aspreva, Bristol-Myers Squibb, Coley, Genentech Pharmaceutical, Human Genome Science, La Jolla Pharmaceutical, Pfizer, and Johnson & Johnson (less than $10,000 each) and has provided expert testimony for Grossman and Roth Attorneys-at-Law on one occasion in 2004.
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Research Article
You have full text access to this OnlineOpen article
The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial
Article first published online: 30 OCT 2006
DOI: 10.1002/art.22198
Copyright © 2006 by the American College of Rheumatology
Additional Information
How to Cite
Tseng, C.-E., Buyon, J. P., Kim, M., Belmont, H. M., Mackay, M., Diamond, B., Marder, G., Rosenthal, P., Haines, K., Ilie, V. and Abramson, S. B. (2006), The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: Findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism, 54: 3623–3632. doi: 10.1002/art.22198
Publication History
- Issue published online: 30 OCT 2006
- Article first published online: 30 OCT 2006
- Manuscript Accepted: 2 AUG 2006
- Manuscript Received: 7 NOV 2005
Funded by
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Grant Number: NIAMS-026
- NIH. Grant Number: NIH R01-AR-44690
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , B-cell numbers and phenotype at clinical relapse following rituximab therapy differ in SLE patients according to anti-dsDNA antibody levels, Rheumatology, 2012,
- 2, , , BAFF and innate immunity: new therapeutic targets for systemic lupus erythematosus, Immunology and Cell Biology, 2012, 90, 3, 293
- 3
- 4, , , , Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period, Arthritis Care & Research, 2012, 64, 4Direct Link:
- 5
- 6
- 7, , , , , , Associations between Ambient Fine Particulate Levels and Disease Activity in Patients with Systemic Lupus Erythematosus (SLE), Environmental Health Perspectives, 2010, 119, 1, 45
- 8, , , , Autologous Hematopoietic Stem Cell Transplantation for Childhood Autoimmune Disease, Pediatric Clinics of North America, 2010, 57, 1, 239
- 9, , , , , , , , , , , , Comparison of the Farr radioimmunoassay, 3 commercial enzyme immunoassays and Crithidia luciliae immunofluorescence test for diagnosis and activity assessment of systemic lupus erythematosus, Clinica Chimica Acta, 2010, 411, 13-14, 959
- 10, , , , , , , Myth and reality: practical test system for the measurement of anti-DNA antibodies in the diagnosis of systemic lupus erythematosus (SLE), Journal of Clinical Laboratory Analysis, 2010, 24, 2Direct Link:
- 11, , Systemic Lupus Erythematosus: Safe and Effective Management in Primary Care, Primary Care: Clinics in Office Practice, 2010, 37, 4, 767
- 12, , , , , , , , , , , , , , , The efficacy and safety of abatacept in patients with non–life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, 2010, 62, 10Direct Link:
- 13, , , , The management of systemic lupus erythematosus: Facts and controversies, Clinics in Dermatology, 2010, 28, 3, 330
- 14, , , , What’s new in clinical trials in lupus?, International Journal of Clinical Rheumatology, 2009, 4, 4, 473
- 15
- 16, , , , , , Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial, Arthritis & Rheumatism, 2008, 58, 8Direct Link:
- 17, , Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials, Rheumatology, 2008, 47, 9, 1367
- 18
- 19, , Underlying medical conditions, Best Practice & Research Clinical Obstetrics & Gynaecology, 2008, 22, 5, 847
- 20, A novel means to demonstrate early efficacy of a product in systemic lupus erythematosus, Current Rheumatology Reports, 2007, 9, 6, 427
- 21, Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with SLE, Future Rheumatology, 2007, 2, 2, 139
- 22Biomarkers predict and pre-emptive prednisone therapy averts severe SLE flares, Nature Clinical Practice Rheumatology, 2007, 3, 2, 67
- 23, Effects of glucocorticoids on inflammation and arthritis, Current Opinion in Rheumatology, 2007, 19, 3, 302
- 24, , ModerneTherapie bei systemischem Lupus erythematodes, Zeitschrift für Rheumatologie, 2007, 66, 8, 662
- 25, , Steroid therapy in clinically stable but serologically active systemic lupus erythematosus prevents severe disease flares, Expert Review of Clinical Immunology, 2007, 3, 3, 267
- 26, , , The use of laboratory methods in differential diagnosis and treatment of SLE and antiphospholipid syndrome, Expert Review of Clinical Immunology, 2007, 3, 4, 613
- 27, , The Large Print Giveth and the Small Print Taketh Away: Preemptive treatment of serologically active, clinically quiet systemic lupus erythematosus, Arthritis & Rheumatism, 2006, 54, 11Direct Link: